This study explored the involvement of N-methyl-Daspartate (NMDA) in the effects of l-opioid agonists. A hotplate procedure was used to assess antinociception and tolerance in mice in which the NR1 subunit of the NMDA receptor was reduced [knockdown (KD)] to approximately 10%, and in mice treated with the NMDA antagonist, (-)-6phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid (LY235959). The l opioid agonists, morphine, l-methadone and fentanyl, were approximately three-fold less potent in the NR1 KD mice than in wild-type (WT) controls; however, the development of morphine tolerance and dependence did not differ markedly in the NR1 KD and the WT mice. Acute administration of the NMDA antagonist, LY235959, produced dose-dependent, leftward shifts in the morphine dose-effect curve in the WT mice, but not in the NR1 KD mice. Chronic administration of LY235959 during the morphine tolerance regimen did not attenuate the development of tolerance in the NR1 KD or the WT mice. These results indicate that the NR1 subunit of the NMDA receptor does not play a prominent role in l opioid tolerance.
Introduction
In the central nervous system, glutamate is the most prominent excitatory neurotransmitter and is known to work through several different receptor types, including three different classes of ionotropic receptors: N-methyl-D-aspartate (NMDA), a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and kainate as well as metabotropic glutamate receptors. Among these receptor types, there is substantial evidence to support a modulatory role for the NMDA receptor in the effects of opioids.
Several laboratories have shown that NMDA receptor antagonists can potentiate the acute antinociceptive effects of opioid agonists, both in squirrel monkeys (Allen and Dykstra, 2001; Allen et al., 2003) and rodents (Kozela and Popik, 2002; Nemmani et al., 2004; Craft and Lee, 2005; Fischer et al., 2005; Grisel et al., 2005) . Moreover, administration of NMDA receptor antagonists in combination with morphine reduces the development of tolerance to its antinociceptive effects Dykstra, 1999, 2000; Trujillo, 2000; Bryant et al., 2006; Mendez and Trujillo, 2008) .
Despite a wealth of evidence implicating the involvement of NMDA receptors in morphine antinociception and tolerance, the specific role of the NMDA receptor in mediating these effects remains unclear. Studies with antagonists specific to the NMDA receptor represent a way to investigate the role of NMDA receptors in morphine's effects. Another way to examine these interactions is to take advantage of genetically modified mice. Therefore, this study examined the effects of m-opioid agonists on mice with a hypomorphic allele for the gene encoding the NR1 subunit of the NMDA receptor (Mohn et al., 1999) . Although mice with a full knockout of NR1 protein are not viable, the mice used here express approximately 5-10% of the normal level of NR1, which is sufficient for survival into adulthood. Consistent with the reduced NR1 gene expression, these mutants display less than 10% of functional NMDA receptors in the brain, compared with wild-type (WT) controls. Therefore, these NR1 knockdown (NR1 KD) mice provide a possible model for assessment of the role of the NR1 subunit of the NMDA receptor in the neurobiology of the antinociceptive effects of morphine.
Specifically, this study used a hotplate nociceptive assay to measure the acute antinociceptive effects of morphine and two other m-opioid agonists, l-methadone and fentanyl. Effects of morphine were examined in NR1 KD mice and compared with WT controls as well as in mice that were treated both acutely and chronically with the NMDA antagonist, (-)-6-phosphonomethyl-decahydroisoquinoline-3-carboxylic acid (LY235959). The hotplate procedure was selected here to make direct comparisons with data collected previously in mice that had been treated with NMDA antagonists. In addition, the development of tolerance to and dependence upon morphine was examined in NR1 KD and WT mice. On the basis of the results of several studies reporting that NMDA antagonists can increase the antinociceptive effects of morphine under certain conditions as well as attenuate the development of opioid tolerance, we hypothesized that similar effects would be observed in mice in which the NR1 subunit was knocked down.
Methods

Subjects
Adult male homozygous NR1 receptor-deficient mice and wild-type controls were either provided by Dr Beverly Koller (Department of Genetics, University of North Carolina, USA) or bred and genotyped in the animal facilities of the Psychology Department at the University of North Carolina at Chapel Hill (USA). All mice were generated as described previously (Mohn et al., 1999) and weighed between 23 and 34 g when experiments were conducted. Previous investigations have characterized these mice as NR1 hypomorphs, given that the NR1 gene is not eliminated in these mice, but rather underexpressed. Previous investigations indicate that the NR1 subunit is greatly reduced in all brain regions of these mutant mice (Duncan et al., 2002) . The behavioural phenotype of these mice includes reduced habituation in activity chambers (Mohn et al., 1999) as well as increased acoustic startle responses and deficits in prepulse inhibition (Duncan et al., 2004) .
The mice were group housed with four to five mice per cage in standard Plexiglas cages in a colony room maintained on a 12-h reversed light/dark cycle (lights off at 07 : 00 h). All mice had continuous access to food and water throughout the study. Mice were also handled and adapted to the testing environment for 2 days prior to initiation of an experiment. All testing procedures were conducted between 09 : 00 and 14 : 00 h. Animals used in this study were cared for in accordance with the guidelines of the Institutional Animal Care and Use Committee of the University of North Carolina at Chapel Hill and the 2010 Guidelines for the Care and Use of Laboratory Animals of the National Institutes of Health.
Antinociceptive procedure
Antinociception was assessed using a hotplate analgesia metre (25.3 Â 25.3 cm) (Columbus Instruments, Columbus, Ohio, USA) maintained at 56 ± 0.18C. The antinociceptive response was evaluated by recording the latency to lick or flutter the hindpaw(s), or to jump from the hotplate surface. Responses were measured using a stopwatch to the nearest 0.1 s. To prevent tissue damage, a cut-off time of 20 s was defined as the maximal response. Immediately after the termination of a trial, mice were removed from the hotplate surface.
An additional experiment was run to determine whether the NR1 receptor knockdown mice and their wild-type littermates differed in their baseline responses on the hot plate. In this experiment, responses to a full range of temperatures were examined in NR1 KD and WT mice, from 44 ± 0.1 to 56 ± 0.18C.
Baseline response latencies on the hot plate were determined twice prior to the beginning of drug administration and were spaced 30 min apart. Data from these determinations were averaged to yield one baseline value. After baseline latency measurements, responding on the hot plate was examined over multiple cycles, spaced either 15 min apart (fentanyl) or 30-min (morphine, l-methadone) apart. Drugs were administered at the start of each cycle and latency on the hot place was determined during the last minute of the cycle. Drug doses were increased cumulatively, with the dose administered increasing in one-quarter or one-half log unit increments prior to each cycle.
Tolerance regimen
Data collected during the acute phase of the study (described above) indicated that the effective dose 50s (ED 50 s) for morphine in the NR1 KD mice were larger than those in the WT mice. Therefore, the tolerance regimen was adjusted based on individual sensitivities of the WT and NR1 KD mice, rather than the administration of the same dose of morphine to all mice. The appropriateness of using a tolerance regimen which is adjusted to each animal's individual sensitivity is described by Barrett et al. (2001) .
Specifically, morphine dose-effect curves were first obtained on the morning of day 1 (prechronic). On the basis of these prechronic morphine dose-effect curves, an individual ED 50 value was determined for each mouse. The tolerance regimen was then initiated, with morphine doses adjusted on the basis of each mouse's prechronic ED 50 value. According to this regimen, each mouse received 5 Â its individual ED 50 on the morning and evening of day 2; 10 Â its individual ED 50 on the morning and evening of day 3; 15 Â its individual ED 50 on the morning and evening of day 4 and 20 Â its individual ED 50 on the morning and evening of days 5-13. On the next day (day 14), the postchronic morphine dose-effect curve was determined, coinciding with the time of the regularly scheduled morning injection. Given this regimen, it should be noted that the NR1 KD mice actually received larger absolute doses than the WT mice; however, the functional dose was the same for each mouse.
In an additional set of experiments, mice received a dose of 1.0 mg/kg of LY235959 throughout the tolerance regimen. These experiments paralleled the tolerance regimen described above. That is, on day 1, a morphine dose-effect curve was determined for each mouse and individual ED 50 values were calculated. The tolerance regimen was then initiated, based on each mouse's ED 50 value; however, mice received 1.0 mg/kg of the NMDA antagonist, LY235959, in combination with increasing doses of morphine throughout the 12-day morphine tolerance regimen as well as on test day.
Withdrawal jumping
Immediately after determining the postchronic morphine dose-effect curve, mice were given an additional morphine injection to raise their cumulative morphine levels to 20 Â their original ED 50 . Naltrexone (1.0 mg/kg) was administered 30 min later, and mice were placed in a 4 liter glass beaker (Pyrex, Lowell, Massachusetts, USA) for a 30-min period. The number of jumps, paw flutters and 'wet-dog shakes' were recorded for each 5-min interval.
Drugs
Morphine sulphate was provided by the National Institute on Drug Abuse (Bethesda, Maryland, USA); l-methadone and LY235959 by Lilly Research Laboratories (Indianapolis, Indiana, USA) or purchased from Tocris Bioscience (Ellisville, Missouri, USA). Fentanyl and naltrexone were purchased from Sigma Chemical Co. (St Louis, Missouri, USA). Drugs were dissolved in 0.9% saline or distilled water to yield all concentrations. All doses were injected subcutaneously at a volume of 0.1 ml/10 g.
Data analysis
Drug effects were expressed as a percentage of the maximal possible effect (% MPE) using the following formula:
% MPE ¼ ½Postdrug latency ðsÞ À baseline latency ðsÞ ½cutoff time ð20sÞ À baseline latency ðsÞ :
Data are expressed as the mean percentage of the maximal possible effect (± standard error of the mean). ED 50 values and 95% confidence limits were calculated using PHARM/PCS version 4 (MicroComputer Specialists, Inc., Philadelphia, Pennsylvania, USA) (Tallarida and Murray, 1987) . When appropriate, statistical analyses were carried out using a t-test or repeated-measures analysis of variance. Post-hoc tests were then conducted to assess the specific group differences. Fisher's protected least significant difference analysis was carried out to determine points that were significantly different from baseline. All analyses were carried out with an a level of significance set at P value of 0.05 or less.
Results Figure 1 shows a temperature-effect curve for NR1 KD mice and the WT controls. Analysis of variance confirmed an effect of temperature, but no effect of genotype. . Although response latencies did not differ between the NR1 KD and WT mice when examined on the hot plate, informal observations indicated that the NR1 KD mice did show increased activity levels in their cages and also when they were handled for injections. Figure 2 shows the effects of morphine, l-methadone and fentanyl in the NR1 KD mice and their WT controls. The ED 50 value (95% confidence limits) for morphine in WT mice was 2.54 mg/kg (1.76-3.67 mg/kg) and 10.39 mg/kg (8.57-12.40 mg/kg) in the NR1 KD mice, yielding a potency ratio of 4.09, indicating that morphine was approximately four times more potent in WT mice than in the NR1 KD mice. The effects of l-methadone were similar to those observed with morphine, with l-methadone being approximately four times more potent in the WT mice than in NR1 KD mice (potency ratio = 3.85). Specifically, the l-methadone ED 50 value (95% confidence limits) was 1.02 mg/kg (0.72-1.44 mg/kg) in the WT mice and 3.93 mg/kg (3.03-5.09 mg/kg) in the NR1 KD mice. The profile of effects obtained for fentanyl was similar to those observed with morphine and l-methadone. That is, the ED 50 for fentanyl in the WT mice was 0.05 mg/kg (0.04-0.06 mg/kg), whereas the ED 50 for fentanyl in the NR1 KD mice was 0.12 mg/kg (0.11-0.14 mg/kg), yielding a potency ratio of 2.36 (1.93-2.89). In both groups of mice, fentanyl was more potent than methadone, which was more potent than morphine. Morphine and l-methadone dose-effect curves were subsequently redetermined after pretreatment with the opioid receptor antagonist, naltrexone. A dose of 1.0 mg/kg naltrexone attenuated the antinociceptive effects of both morphine and l-methadone in a comparable manner, producing a three-fold to five-fold rightward shift in the morphine and l-methadone dose-effect curves in both NR1 KD and WT mice. The ED 50 (95% confidence limits) values for morphine and l-methadone alone and in combination with naltrexone are shown in Table 1 . Figure 3 shows the effects of morphine after a regimen of chronic morphine administration. The effects of morphine prior to tolerance induction were similar to those shown in Figure 2 . That is, morphine produced dosedependent increases in latency to respond on the hot plate in both NR1 KD and WT mice; however, morphine was less potent in the NR1 KD mice, yielding an ED 50 of 7.79 mg/kg (5.86-10.36 mg/kg) in the NR1 KD mice and an ED 50 of 2.88 mg/kg (2.18-3.80 mg/kg) in the WT mice. After 12 days of chronic morphine administration, with the dose of morphine increased by the same proportion in each individual mouse, the morphine dose-effect curve shifted to the right, yielding an ED 50 of 30.15 mg/kg (23.54-38.61 mg/kg) in the NR1 KD mice and an ED 50 of 9.06 mg/kg (7.16-11.47 mg/kg) in the WT mice, with the magnitude of the shift in the morphine dose-effect curve being approximately the same, that is, 3.1-3.9-fold in the WT and NR1 KD mice, respectively.
After the postchronic morphine dose-effect curve was determined, mice were administered naltrexone and observed for signs of withdrawal. During the 30-min observation period, typical signs of withdrawal were observed in both WT and NR1 KD mice, including occasional paw tremors and wet dog shakes. The most prominent sign of withdrawal, jumping behaviour, is shown in Figure 4 , averaged over a 15-min or a 30-min observation period. The number of jumps that occurred during the first 15-min period of the 30-min observation period were significantly less in the NR1 KD mice as compared with the WT mice (P = 0.05); however, when the data were averaged across the entire 30-min period, no significant differences were observed between the genotypes (P = 0.34). Figure 5 shows the effects of acute pretreatment with the competitive NMDA receptor antagonist, LY235959, on the morphine dose-effect curve in both WT and NR1 KD mice. The ED 50 for morphine alone was 5.54 mg/kg (4.57-6.72 mg/kg) in the WT mice (top) and 9.22 mg/kg (6.82-12.47 mg/kg) in the NR1 KD mice (bottom). LY235959 did not produce consistent shifts in the morphine dose-effect curve in the NR1 KD mice; however, it did produce leftward shifts in the morphine dose-effect curve in the WT mice. Specifically, the morphine ED 50 was 2.82 mg/kg (2.11-3.79 mg/kg) after 0.32 mg/kg of LY235959 and 2.02 mg/kg (1.32-3.10 mg/kg) after 1.0 mg/kg of LY235959. Table 2 shows the effects of chronic administration of 1.0 mg/kg LY235959 throughout the tolerance regimen and on test day. The effects of morphine prior to and subsequent to the development of tolerance were similar to those observed previously. That is, after 12 days of morphine administration in mice that received saline concurrently, the morphine ED 50 increased 2.59-fold and 2.80-fold, in the NR1 KD and WT mice, respectively. In separate groups of NR1 KD and WT mice that received a 1.0 mg/kg dose of LY235959 throughout the tolerance regimen, the morphine ED 50 increased 3.24-fold and 7.03-fold, in the NR1 KD mice and WT mice, respectively. Therefore, rather than attenuating the development of morphine tolerance, as hypothesized, it appears that chronic administration of 1.0 mg/kg of LY235959 either did not shift the morphine curve or actually shifted the morphine curve further to the right.
Discussion
This study used mice with significantly reduced NR1 subunit expression to examine the role of the NMDA receptor system in mediating the acute antinociceptive effects of a range of opioid agonists as well as the development of tolerance and dependence upon morphine.
Results from this study regarding the antinociceptive effects of m-opioids in WT mice indicate that fentanyl is more potent than methadone, which is more potent than morphine. This potency relationship is in agreement with well-established findings regarding the efficacy of m-opioids (e.g. Colpaert and Niemegeers, 1975; Colpaert et al., 1976) . The same potency relationship was observed in the NR1 KD mice; however, all three m opioid agonists were approximately 2-4 times less potent in the NR1 KD mice than in the WT mice.
The differences in m opioid potency between the NR1 KD and WT mice cannot be explained by differences in baseline sensitivities as the NR1 KD and WT mice were equally sensitive to a range of temperatures on the hot plate. This observation agrees with another study in which paw withdrawal latencies in response to a noxious thermal stimulus were not different in cortex-specific NR1 knockout mice and C57BL/6 control mice; however, cortex-specific NR1 KD mice did show less nociception than the control mice in a formalin test (Quintero et al., 2007) . Moreover, it has been shown that a conditional deletion of the NR1 subunit of the NMDA receptor in adult spinal cord dorsal horn reduces pain in response to injury (South et al., 2003) .
The fact that no differences in baseline nociception were observed in the present study, in which the hotplate procedure was used to assess antinociception, may be due to the type of procedure used to examine antinociception or to differences in the specificity of alterations of the NR1 subunit. For example, the studies referred to above (Quintero et al., 2007; South et al., 2003) , which have reported decreased nociception in NR1 KD mice in comparison with control mice, have examined situations involving tonic nociception (e.g. formalin test, injury induced pain) versus nociception in response to an acute thermal stimulus, as used in this study. Moreover, these same studies have examined mice with a conditional and/or cortex-specific deletion of the NR1 subunit rather than a global knockdown of up to 90%, as was the case in this study.
Although the m-opioids examined here were less potent in the NR1 KD mice than in the WT mice, the mice did not differ when other aspects of opioid pharmacology were examined. The effects of both morphine and l-methadone were antagonized by naltrexone to an equivalent degree in the NR1 KD and WT mice; morphine tolerance developed to the same extent in both NR1 KD and WT mice, and although there was some suggestion that signs of physical withdrawal may have occurred somewhat later in the NR1 KD mice than in the WT mice, differences in withdrawal jumping were not significant when withdrawal jumps were observed over a longer time period. Taken together, these data suggest that the m opioid receptor system is not altered in NR1 KD mice.
The findings regarding the development of morphine tolerance are particularly interesting because previous research has shown that NMDA antagonists can attenuate the development of tolerance. (e.g. Dykstra, 1999, 2000; Trujillo, 2000; Bryant et al., 2006; Mendez and Trujillo, 2008) . On the basis of these findings, we had predicted that tolerance would be attenuated in the NR1 KD mice. In this context, it is important to emphasize the way in which the tolerance regimen was carried out in this study.
Typically, when the development of tolerance is examined between different groups of animals, each group receives the same dose and/or administration schedule during a chronic regimen and then postchronic (n = 9) 9.85 (7. 66-12.67) 31.97 (18.88-54.11) 3.24 (1.97-5.35) CL, confidence limits; KD, knockdown; WT, wild type. dose-effect curves are compared between groups. As morphine was less potent in the NR1 KD mice, as compared with WT mice, the tolerance regimen in this study was adjusted, based on individual morphine ED 50 s obtained in the WT and NR1 KD mice. As a result, the NR1 KD mice actually received a greater absolute dose of morphine throughout the tolerance regimen, given that their prechronic ED 50 s were approximately three times larger than the ED 50 s obtained in the WT mice. As it is well-established that the magnitude of morphine tolerance is greater when larger doses of morphine are administered (Adams and Holtzman, 1990; Colpaert, 1996; Hoffman et al., 1998) , one might expect to see a greater degree of tolerance with the NR1 KD mice as they actually received a larger amount of morphine during the tolerance regimen. Nevertheless, tolerance developed to an equivalent degree in both the NR1 KD and WT mice, with the ED 50 s increasing approximately threefold in both the NR1 KD and the WT mice.
At least one study that examined the development of morphine tolerance in mice lacking the gene encoding the GluRE1 subunit of the NMDA receptor (also referred to as the NR2 subunit) reported that morphine tolerance was attenuated in the genetically-modified mice as compared with C57BL/6J mice (Inoue et al., 2003) . Nevertheless, the dose of morphine used in Inoue et al.'s (2003) study to establish tolerance (10 mg/kg) was the same in both groups, even though the mice lacking the NMDA receptor GluRE1 (or NR2) subunit gene were more sensitive to the antinociceptive effects of morphine than the C57BL/6J controls. Therefore, when comparing the development of tolerance between groups of mice that differ in some way, it is important to accommodate these differences by adjusting the amount of drug administered during the tolerance regimen, based on the acute sensitivity of animals within each group (see Barrett et al., 2001 for a discussion of this issue).
It is also interesting that the differences in potency observed between the NR1 KD mice and their WT littermates were actually in the opposite direction than what was predicted, based on previous studies in our laboratory examining the acute effects of morphine in combination with a range of NMDA antagonists. Indeed, our laboratory has shown that doses of the NMDA antagonist, LY235959, that had no antinociceptive effects when examined alone, produce leftward shifts in the morphine dose-effect curve in both squirrel monkeys (Allen and Dykstra, 2001) and mice (Fischer and Dykstra, 2006) . This observation was also replicated in this study in which doses of 0.32 and 1.0 mg/kg of LY235959 shifted the morphine dose-effect curve to the left in WT mice; however, no shifts were observed in the NR1 KD mice.
There are a number of reasons why differences might be observed between the acute effects of an NMDA antagonist and the prolonged reduction in NMDA receptor function through genetic manipulation. The NR1 KD mice examined in this study have been described as NR1 hypomorphs given that NR1 binding sites in these mice show both a marked and a global reduction (Mohn et al., 1999; Duncan et al., 2002) . Therefore, acute administration of an NMDA antagonist is likely to produce different effects than what might occur when receptor function undergoes long-term reduction. In NR1 KD mice, NMDA receptor function is impaired throughout development and remains through adulthood. Clearly, this provides many opportunities for compensatory functions to develop. Indeed, the relatively subtle nature of the metabolic alterations observed in NR1 KD mice, despite a marked reduction in the expression of the NR1 subunit, suggests the presence of compensatory responses (Duncan et al., 2004) .
Secondly, although the NR1 subunit is a critical component of the entire NMDA receptor complex, the consequences of a 90% reduction in the NR1 subunit upon other subunits of the NMDA receptor is not well known. For example, significant global reductions in NR2A and NR2B protein levels have been reported in NR1 KD mice (Ramsey et al., 2008) . Mice deficient in the NR2A subunit (also called the GluRE1 subunit) of the NMDA receptor did not reveal altered responses to painful stimuli in assays of allodynia or hyperalgesia (Petrenko et al., 2003) ; however, the antinociceptive effects of morphine in a tail pinch procedure were enhanced in the NR2A (or GluRE1) deficient mice (Inoue et al., 2003) . Clearly, additional data are required to determine the contribution of each of these variables (i.e. the specific NR subunit examined, type of analgesic procedure used, etc.) to interactions between opioid receptor function and the NMDA system.
Finally, this study suggests that the withdrawal signs after chronic administration of morphine were not different between the WT and NR1 KD mice. These findings are similar to those reported by Glass et al. (2008) in which they showed that bilateral local NR1 gene deletion did not alter either the somatic or visceral symptoms of withdrawal precipitated by naloxone in morphine-treated mice.
The results obtained here indicate that alterations in m opioid antinociception and tolerance in NR1 KD mice do not parallel the effects produced by either the acute or chronic administration of an NMDA antagonist. Taken together these results suggest that m opioid receptor function is not changed in mice that express low levels of the NR1 subunit of the NMDA receptor.
